Latest news with #thrombectomy
Yahoo
10-07-2025
- Business
- Yahoo
Penumbra (PEN) Announces Completion of Enrollment in STORM-PE Clinical Trial
Penumbra, Inc. (NYSE:PEN) is one of the The company announced the completion of enrollment in STORM-PE clinical trial. The pivotal, prospective, multi-center randomized controlled trial has enrolled 100 patients in order to evaluate computer assisted vacuum thrombectomy (CAVT) through utilising Penumbra's Lightning Flash™ plus anticoagulation, versus anticoagulation alone, for treating acute intermediate-high risk pulmonary embolism (PE). An operating theatre showcasing medical solutions from the company. In the US, an estimated 900,000 cases of symptomatic PE take place annually. Pulmonary embolism could be life-threatening, with 10% – 30% of individuals dying within 1 month of diagnosis. Penumbra, Inc. (NYSE:PEN)'s Lightning Flash portfolio happens to be the most advanced mechanical thrombectomy system on the market, focused on addressing venous and pulmonary thrombus. Penumbra, Inc. (NYSE:PEN)'s gross profit for Q1 2025 came in at $215.9 million, or 66.6% of total revenue, compared to $181.1 million, or 65.0% of total revenue, for Q1 2024. This improvement in gross margin was mainly because of favorable product mix throughout the regions and productivity improvements. Penumbra, Inc. (NYSE:PEN) increased its guidance for the U.S. Thrombectomy franchise growth to 20% – 21% YoY from 19% – 20% previously. It reiterated the guidance for gross margin expansion of a minimum of 100 bps in 2025, to over 67% for FY 2025. Baron Funds, an investment management company, released its Q1 2025 investor letter. Here is what the fund said: 'We initiated a position in Penumbra, Inc. (NYSE:PEN), a leading manufacturer of medical devices that remove blood clots from veins and arteries. Physicians use the company's devices to treat pulmonary embolism (PE), deep vein thrombosis (DVT), acute limb ischemia, ischemic stroke, coronary disease, and other conditions. Penumbra's devices, which are called mechanical thrombectomy devices, use computer algorithms to modulate the aspiration power depending on if a clot is detected and to control a separate valve that injects saline to reduce friction between the clot and catheter. This enables a differentiated device profile that maximizes clot removal with speed while decreasing risk of blood loss. While we acknowledge the potential of PEN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CBS News
02-07-2025
- Health
- CBS News
Stanford researchers unveil breakthrough for treating blood clots in stroke, heart attack patients
Stanford researchers have discovered a breakthrough technology to eliminate blood clots to treat strokes, heart attacks, and other clot-related diseases. Stroke is one of the leading causes of death and disability worldwide. It happens when a clot blocks blood flow in the brain. Time is crucial when treating stroke patients. During a stroke, millions of neurons die every second, causing permanent, irreversible damage to the brain. The researchers came up with a new, life-saving way to shrink and remove these damaging clots. The technology is called a milli-spinner thrombectomy. Renee Zhao, assistant professor of mechanical engineering at Stanford University, is leading breakthrough technology in treating stroke patients. "This new technology is extremely exciting because we physically developed the first mechanism to shrink the size of the clot, so we can shrink the clot from its original size to just 5% of its original volume," said Renee Zhao, assistant professor of mechanical engineering at Stanford University. Currently, the only way to treat stroke patients is to either inject a tissue plasminogen activator (tPA), a chemical to dissolve the clot, which only works in the first few hours. The clot can then be removed through aspiration thrombectomy, sucking it out like a vacuum machine or through mechanical thrombectomy stent removal to pull out the clot. The problem with both cases is that the clot can easily break apart, fragmenting into smaller pieces that could move into extremely difficult places to reach. Zhao said their the milli-spinner thrombectomy invention actually changes the microstructure of the clot. "This is very similar to the microstructure of a clot," said Zhao. "It's a bunch of fiber networks, and it's very loosely distributed. And now what the spinner is doing is that when it rotates, it generates a sheer force. It's like my palm applying a sheer force just like that, so it densifies the fiber network. Eventually, what we see is a highly-densified fiber core." The incredible thing is that Zhao and her researchers were completely surprised by their invention, never expecting to see the clot transform before their eyes. "Interestingly, we found a very exciting phenomenon," said Zhao. "We physically saw the clot start to turn white because a clot is red and it has all the red blood cells in the fiber network, but it turned white! That's bizarre! Basically, we've never seen anything like that." "The first step is I'm going to load our milli-spinner into the catheter," said Stanford 4th-year Ph. D. student Yilong Chang. "Here's what our milli-spinner looks like. It's 1.2 millimeter in diameter. It's very small. It has a unique geometry with a hole in the front and four slits on the side." Researchers gave us a demo of the milli-spinner in action, showing us exactly how it works and how quickly it can remove a clot. "Now I still feel this mechanism is not something that someone can easily come up with a clot treatment strategy by extracting the fiber," said Zhao. "Nobody would think of that, so the key point of the way we do research is always feel free and open to the unexpected findings, and they will always give us something that is beyond imagination!" The spirit of Zhao's lab is one of curiosity, creativity and exploration. She said true innovation comes when you embrace the unexpected. It's this passion that drives the advancements of her lab's impressive scientific discoveries. Zhao's new technology, published last month in the scientific journal Nature, is more than twice as effective as current techniques. Zhao and her team of researchers are hoping to perform their first trial on a human next year.
Medscape
18-06-2025
- Health
- Medscape
Head Position Matters in Stroke Care Before Thrombectomy
A flat 0° head positioning before thrombectomy was associated with a significantly less risk for early neurologic deterioration and all-cause mortality than a conventional 30° head elevation in adults with large vessel occlusion (LVO) stroke, a new study showed. METHODOLOGY: Researchers conducted the prospective, multicenter ZODIAC trial from 2018 to 2023 with 92 patients (mean age, 67 years; 52% men). All had LVO stroke confirmed on CT angiography and a viable penumbra and were eligible for thrombectomy within 24 hours of stroke. Participants were randomly assigned to receive either 0° (n = 45) or 30° (n = 47) head-of-bed positioning before thrombectomy. National Institutes of Health Stroke Scale (NIHSS) scores were assessed every 10 minutes until thrombectomy began. The primary endpoint was early neurologic deterioration, defined as a worsening of ≥ 2 NIHSS points before thrombectomy. Additional outcomes were severe neurologic deterioration (worsening of ≥ 4 NIHSS points) before thrombectomy, hospital-acquired pneumonia, and all-cause death within 3 months. TAKEAWAY: Early neurologic deterioration was more common in the 30° group than in the 0° group (55% vs 2%; hazard ratio [HR], 34.4; P < .001), as was severe neurologic deterioration (n = 20 vs n = 1; HR, 23.6; P = .002). < .001), as was severe neurologic deterioration (n = 20 vs n = 1; HR, 23.6; = .002). The all-cause mortality rate at 90 days was significantly lower in the 0° group than in the 30° group (4% vs 22%; P = .03). = .03). A greater proportion of patients in the 0° group than in the 30° group showed neurologic improvement at 24 hours post-thrombectomy (87% vs 60%; odds ratio, 0.2; P = .01). = .01). No participant in either group developed hospital-acquired pneumonia. IN PRACTICE: 'Results suggest that patients awaiting thrombectomy treatment for LVO stroke should be positioned with the head at 0° to ensure clinical stability and prevent worsening,' the investigators wrote. 'We posit that 0° head positioning is a bridging maneuver to thrombectomy, protecting ischemic tissue and possibly reducing infarct progression before definitive treatment,' they added. SOURCE: This study was led by Anne W. Alexandrov, PhD, University of Tennessee Health Science Center, Memphis, Tennessee. It was published online on June 04 in JAMA Neurology . LIMITATIONS: This study was limited by its small sample size and early termination, the lack of blinding to head position, and the exclusion of data on thrombectomy decisions. Additionally, patients transferred between facilities were excluded, which may have affected the 3-month outcomes. DISCLOSURES: Funding was provided by the NIH. Several investigators reported receiving a grant or per-patient payment from NIH during the study. One also reported being a paid co-investigator on the NIH grant for imaging core lab services. Full details are listed in the original article.
Associated Press
18-06-2025
- Business
- Associated Press
ANACONDA Biomed Receives CE Mark for Its ANA5 Funnel Catheter to Treat Ischemic Stroke
BARCELONA, Spain--(BUSINESS WIRE)--Jun 18, 2025-- ANACONDA Biomed, a medical technology company developing next-generation thrombectomy systems for the treatment of ischemic stroke, has announced that it has received CE Mark certification for its ANA5 Funnel Catheter. The CE marking confirms that the ANA5 device complies with the European Union's health, safety, and environmental protection standards, enabling its eventual commercial viability across the EU. This press release features multimedia. View the full release here: The ANA5 Funnel Catheter is engineered to optimize mechanical thrombectomy by maximizing clot capture with its vessel-matching diameter funnel. Simultaneously, it enables antegrade flow arrest and offers the potential for flow reversal, enhancing aspiration-assisted clot retrieval. The ANA5 promotes improved clot capture and removal through its unique proprietary geometry. The ANA5 Funnel Catheter is engineered to optimize mechanical thrombectomy by maximizing clot capture with its vessel-matching diameter funnel. Simultaneously, it enables antegrade flow arrest and offers the potential for flow reversal, enhancing aspiration-assisted clot retrieval. The ANA5 promotes improved clot capture and removal through its unique proprietary geometry. The CE Mark approval is supported by a comprehensive body of evidence, including preclinical bench and animal studies, and clinical data from the recently published ANAIS study demonstrating high reperfusion and first-pass success rates. Further clinical validation is ongoing in the ATHENA trial, a prospective, multicenter randomized study systematically evaluating the impact of proximal flow arrest on reperfusion effectiveness, to support future regulatory submissions and commercialization efforts in the United States. ' Receiving CE Mark approval is a pivotal achievement for ANACONDA Biomed thatadvances our mission to innovate in the interventional management of acute ischemic stroke,' said Trent Reutiman, chief executive officer. " This milestone reflects the strength of our science and the dedication of our team. We now have the capability of making ANA5 available to clinicians across Europe, bringing this innovative technology to broader stroke application.' Dr. Marc Ribo, the co-founder of Anaconda Biomed, added, " Receiving CE Mark approval for ANA5 is deeply meaningful, as it represents the culmination of years of research, iteration, and belief in an idea that began at the bench. This is more than a regulatory milestone; it's the moment where innovation becomes impact. We're now gearing up to capture real-world data by collecting more invaluable insight into how ANA5 performs across diverse stroke centers and clinical realities. ' About ANA Funnel Catheter ANA5 Advanced Neurovascular Access™ (ANA Funnel Catheter) is designed as an expandable and collapsable funnel catheter for interventional neurovascular procedures, requiring the retrieval of clot, and benefiting from limiting flow and/or flow reversal towards that goal. The device consists of a radiopaque nitinol braid funnel, covered with a polymeric coating enabling local flow arrest. The catheter is currently an investigational device and is not available for sale in the United States. About Anaconda Biomed Anaconda Biomed is an innovative medical technology company dedicated to developing next-generation thrombectomy systems for the treatment of ischemic stroke. At the heart of its product portfolio is the ANA Funnel Catheter. Anaconda Biomed has received funding from prominent life science investment firms, including Ysios Capital, Omega Funds, Innogest, Asabys Partners, Banco Sabadell, and private investors. Additionally, through public grants, the company has received significant public support from ENISA, CDTI (Innvierte and NEOTEC), the Ministry of Science & Innovation (Emplea and Retos), EIB, and EIT Health. For more information, please visit and follow the company on LinkedIn. View source version on CONTACT: MEDIA CONTACT: Joe Duraes Pazanga Health Communications [email protected] 917-687-6419 KEYWORD: SPAIN EUROPE INDUSTRY KEYWORD: SURGERY MEDICAL DEVICES HEALTH CLINICAL TRIALS CARDIOLOGY SOURCE: Anaconda Biomed Copyright Business Wire 2025. PUB: 06/18/2025 07:05 AM/DISC: 06/18/2025 07:03 AM
Fox News
16-06-2025
- Health
- Fox News
Stanford researchers develop ‘game-changing' stroke treatment that doubles effectiveness
Researchers at Stanford University say they have developed a more effective way to treat strokes. The new technology, called the milli-spinner thrombectomy, has been shown to have more successful outcomes for patients who have experienced strokes, as well as heart attacks, pulmonary embolisms and other clot-related diseases, according to a press release from the university. Blood clots are clumped together by thread-like proteins called fibrin. The milli-spinner — which is a long, hollow, rotating tube with a series of "fins and slits" — enters the body through a catheter and applies force and suction to the clot. As a result, the blood clot is reduced in size — down to as little as 5% of its original volume — without breaking any of the fibrin threads. That's important because breaking up the clot can result in pieces of it escaping and getting stuck in hard-to-reach places, the researchers noted. With the milli-spinner, red blood cells are "freed" and the much smaller fibrin clot is removed from the body. "With existing technology, there's no way to reduce the size of the clot. They rely on deforming and rupturing the clot to remove it," said senior author Renee Zhao, an assistant professor of mechanical engineering, in the release. "What's unique about the milli-spinner is that it applies compression and shear forces to shrink the entire clot, dramatically reducing the volume without causing rupture." Time is of the essence when treating an ischemic stroke, which is when the clot is cutting off oxygen to the brain. Studies have shown that for every minute during a stroke, 1.9 million brain neurons and 14 billion synapses are destroyed. With current technologies, clots are only removed about half the time on the first try, the release stated, and they fail completely about 15% of the time. "For most cases, we're more than doubling the efficacy of current technology, and for the toughest clots – which we're only removing about 11% of the time with current devices – we're getting the artery open on the first try 90% of the time," said co-author Jeremy Heit, chief of neuroimaging and neurointervention at Stanford, in the release. "This is a sea-change technology that will drastically improve our ability to help people." The researchers' findings, which incorporated both animal studies and machine-based flow models, were published June 4 in the journal Nature. The multi-spinner could potentially be used for other applications, such as capturing and removing kidney stone fragments, the release noted. The team is now working to get the new technology approved for clinical use, with clinical trials expected to begin soon. "What makes this technology truly exciting is its unique mechanism to actively reshape and compact clots, rather than just extracting them," Zhao said. "We're working to bring this into clinical settings, where it could significantly boost the success rate of thrombectomy procedures and save patients' lives." For more Health articles, visit Fox News Digital reached out to the researchers and cardiologists for comment.
